The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...

The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently ...

UNITY Biotechnology stock loses 29% as the mid-stage DME study of the lead candidate, UBX1325, fails to achieve statistical ...

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...

in a patent case over Regeneron's blockbuster Eylea drug was affirmed by an appeals court. "We have considered Regeneron's remaining arguments and find them unpersuasive," the appeals court wrote ...

Eylea has been a significant revenue driver for Regeneron, and any potential impact on its sales due to competition from biosimilars is closely watched by investors. The court’s ruling thus represents ...

Regeneron Pharmaceuticals, Inc. is a well-managed company with a diverse pipeline, but faces the likely decline in revenues from its key drug, Eylea. The loss of Eylea's patent protection has led ...

Adds Regeneron comment Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 1.6% after the company's loss against Amgen (NASDAQ:AMGN) in a patent case over Regeneron's blockbuster Eylea drug was affirmed ...

Opthea was making preparations for the potential launch of a new eye disease drug onto the market. | A month ago, Opthea was ...

The data readout from the mid-stage DME study demonstrated that treatment with the candidate resulted in vision gains, non-inferior to Regeneron’s Eylea, at weeks 24 and 36 in the difficult-to ...

Eylea biosimilar, which UBS analyst Trung Huynh tells investors in “negative, but somewhat expected” for Regeneron (REGN). While extended timelines for an additional appeal is likely ...

As a result of the ruling, Amgen, which produces a biosimilar for Eylea, saw its shares increase by as much as 0.5%. This legal setback for Regeneron comes amid competitive pressures in the ...